Patient & Visitor InformationContact Us
  • Cantos Study

  • Cantos Trial

    A randomized, double-blind, placebo-controlled, event driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP

    Inclusion Criteria:
    • Documented MI
    • hsCRP> 2mg/L at 30 days post MI
    Exclusion Criteria:
    • History of TB
    Key points:
    To evaluate the benefit of quarterly subcutaneous canakinumab doses compared to placebo among stable post-MI patients receiving standard of care therapy who have been selected for an elevated inflammatory burden as determined by hsCRP > 2mg/L.

    Duration of trial is up to 36 months.

    For more information, please contact the study coordinator:

    Cardiovascular Research
    The Miriam Hospital
    Lori-Ann DeSimone
    401-793-4105